|
시장보고서
상품코드
2058236
골다공증 치료 및 골절 치유 시장 : 약물 종류별, 투여 경로별, 유통 채널별, 지역별Anti-Osteoporosis And Fracture Healing Market, By Drug Class, By Route of Administration, By Distribution Channel, By Geography |
||||||
골다공증 치료 및 골절 치유 시장은 2026년에 185억 달러로 추정되며, 2033년까지 248억 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 11.3%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 185억 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 11.30% | 2033년 시장 규모 예측: | 248억 달러 |
세계 인구의 고령화, 골다공증 유병률의 증가, 그리고 전 세계 취약성 골절 발생률의 상승에 힘입어 시장은 강력한 성장세를 보이고 있습니다. 뼈 건강에 대한 인식 제고, 골밀도 검사를 통한 진단 접근성 개선, 그리고 치료법의 보급 확대가 시장 성장을 더욱 견인하고 있습니다.
골다공증 치료 및 골절 치유 요법은 골량 감소 방지, 골밀도 개선, 골절 위험 감소, 그리고 골절 후 회복 지원에 있어 매우 중요한 역할을 하고 있습니다. 이 시장에는 비스포스포네이트 제제, 호르몬 대체요법, 단일클론 항체, 골형성 촉진제, 그리고 경구용 및 주사제 형태로 모두 사용되는 기타 첨단 치료제가 포함됩니다. 이 중에서도 비스포스포네이트 제제는 입증된 효능, 합리적인 가격, 그리고 골다공증 관리의 1차 치료제로서 널리 사용되고 있다는 점 덕분에 여전히 시장을 주도하고 있습니다.
바이오의약품, 골형성 촉진 요법, 바이오시밀러 분야의 기술적 진보는 치료 방식을 혁신하고 환자의 예후를 개선하고 있습니다. 또한, 혁신적인 치료법에 대한 규제 당국의 지원 강화, 의료비 증가, 그리고 병원 기반 골절 관리 프로그램의 확대가 세계 시장의 성장을 가속화하고 있습니다. 데노스마브, 로모소주마브, 테리파라티드 등 첨단 치료법의 도입이 급속히 진행되고 있는 점도 시장 내 경쟁 구도를 더욱 치열하게 만들고 있습니다.
시장 역학
골다공증 치료 및 골절 치유 시장은 인구통계, 임상, 의료 관련 여러 요인의 영향으로 상당한 성장을 이루고 있습니다. 주요 성장 요인 중 하나는 전 세계적으로 증가하는 골다공증의 부담입니다. 골다공증은 전 세계적으로 약 2억 명에게 영향을 미치고 있으며, 연간 약 890만 건의 골절 원인이 되어 장기적인 치료 개입 및 골절 관리 솔루션에 대한 지속적인 수요를 창출하고 있습니다.
또 다른 중요한 성장 요인은 급속히 증가하는 고령 인구입니다. 2050년까지 전 세계 인구의 약 6명 중 1명이 65세 이상이 되어, 골다공증 및 관련 골절 위험을 안고 있는 인구가 크게 증가할 것으로 예상됩니다. 폐경 후 여성과 고령자는 여전히 가장 취약한 환자 집단이며, 예방 및 치료에 대한 지속적인 수요를 이끌고 있습니다.
또한, 경구 요법은 편의성이 높고 비침습적인 투여가 가능하며 환자의 복약 순응도도 높아 그 보급이 확대되고 있어 시장을 더욱 뒷받침하고 있습니다. 연구에 따르면, 만성 질환 관리에 있어 환자의 60-70% 이상이 주사제보다 경구약을 선호하는 것으로 나타났습니다. 또한, 골절 관련 입원 건수가 많고 전문의 주도의 골다공증 치료 경로가 확립되어 있어, 병원 약국도 치료제 공급에 있어 중요한 역할을 담당하고 있습니다.
의약품 개발 분야의 지속적인 혁신 또한 시장의 주요 성장 동력 중 하나입니다. 미국 식품의약국(FDA) 등 규제 당국은 패스트트랙(Fast Track) 및 획기적 치료제(Breakthrough Therapy) 지정을 통해 동화 요법 및 생물학적 제제의 승인을 가속화하고 있으며, 차세대 치료법의 신속한 시장 출시를 뒷받침하고 있습니다. 바이오시밀러의 출시와 첨단 단일클론 항체 치료법 또한 선진국 및 신흥국에서 치료 접근성을 개선하고 있습니다.
그러나 생물학적 제제의 높은 치료비, 복약 순응도 문제, 규제 시장에서의 가격 압박과 같은 요인들이 시장 성장을 어느 정도 제한할 가능성이 있습니다. 중국의 물량 중심 조달 및 적극적인 약가 협상 등의 정책은 환자의 접근성이 개선되고 있음에도 불구하고, 제약사의 이익률을 계속해서 압박하고 있습니다. 그럼에도 불구하고, 의료 인프라 확충, 골절 예방에 대한 인식 제고, 의료비 증가가 전 세계 시장의 장기적인 성장을 뒷받침할 것으로 예상됩니다.
본 조사의 주요 특징
- 본 조사에서는 각 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 촉진요인, 시장 억제요인, 기회, 신제품 출시, 시장 동향, 지역별 전망 및 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트를 제공합니다.
- 본 조사에서는 다음의 주요 지표를 바탕으로 골다공증 및 골절 치료 시장의 주요 기업들을 분석하고 있습니다 : 기업 개요, 서비스 포트폴리오, 주요 발전 사항, 재무 실적 및 전략.
- 본 보고서의 인사이트를 활용함으로써, 마케팅 담당자와 경영진은 향후 서비스 혁신, 시장 확대, 전략적 제휴와 관련하여 정보에 기반한 의사결정을 내릴 수 있게 됩니다.
- '골다공증 치료 및 골절 치유 시장' 보고서는 투자자, 서비스 제공업체, 제약사, 규제 당국, 금융 애널리스트 등 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 골다공증 치료 및 골절 치유 시장 평가에 사용되는 체계적인 분석 프레임워크와 전략 매트릭스를 활용함으로써 큰 이점을 얻을 수 있습니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 골다공증 치료 및 골절 치유 시장 : 약물 종류별, 2021-2033년
제5장 세계의 골다공증 치료 및 골절 치유 시장 : 투여 경로별, 2021-2033년
제6장 세계의 골다공증 치료 및 골절 치유 시장 : 유통 채널별, 2021-2033년
제7장 세계의 골다공증 치료 및 골절 치유 시장 : 지역별, 2021-2033년
제8장 경쟁 구도
제9장 섹션
KSMAnti-Osteoporosis And Fracture Healing Market is estimated to be valued at USD 18.5 Bn in 2026 and is expected to reach USD 24.8 Bn by 2033, growing at a compound annual growth rate (CAGR) of 11.3% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 18.5 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 11.30% | 2033 Value Projection: | USD 24.8 Bn |
The market is experiencing strong growth driven by the rapidly aging global population, increasing prevalence of osteoporosis, and rising incidence of fragility fractures worldwide. Growing awareness regarding bone health, improved diagnostic access through bone mineral density screening, and expanding treatment adoption are further supporting market expansion.
Anti-osteoporosis and fracture healing therapies play a critical role in preventing bone loss, improving bone density, reducing fracture risk, and supporting post-fracture recovery. The market includes bisphosphonates, hormone replacement therapies, monoclonal antibodies, anabolic agents, and other advanced therapeutics used across oral and injectable formulations. Among these, bisphosphonates continue to dominate due to their proven efficacy, affordability, and widespread use as first-line therapy for osteoporosis management.
Technological advancements in biologics, anabolic bone-forming therapies, and biosimilars are transforming treatment approaches and improving patient outcomes. In addition, increasing regulatory support for innovative therapies, rising healthcare expenditure, and the expansion of hospital-based fracture management programs are accelerating global market growth. Strong adoption of advanced therapies such as denosumab, romosozumab, and teriparatide is also strengthening the competitive landscape of the market.
Market Dynamics
The Anti-Osteoporosis And Fracture Healing Market is witnessing substantial growth due to multiple demographic, clinical, and healthcare-related factors. One of the primary growth drivers is the increasing burden of osteoporosis globally. Osteoporosis affects nearly 200 million people worldwide and contributes to approximately 8.9 million fractures annually, creating sustained demand for long-term therapeutic intervention and fracture management solutions.
Another significant growth factor is the rapidly expanding geriatric population. By 2050, approximately 1 in 6 people globally will be aged 65 years or older, significantly increasing the population at risk for osteoporosis and related fractures. Postmenopausal women and elderly individuals remain the most vulnerable patient groups, driving continuous demand for preventive and therapeutic treatments.
The market is further supported by strong adoption of oral therapies owing to their convenience, non-invasive administration, and better patient adherence. Studies indicate that more than 60-70% of patients prefer oral medications over injectable alternatives for chronic disease management. Hospital pharmacies also play a major role in treatment distribution due to the high volume of fracture-related hospitalizations and specialist-led osteoporosis care pathways.
Continuous innovation in drug development is another key market driver. Regulatory agencies such as the U.S. Food and Drug Administration are accelerating approvals for anabolic and biologic therapies through fast-track and breakthrough therapy designations, supporting faster commercialization of next-generation treatments. Biosimilar launches and advanced monoclonal antibody therapies are also improving treatment accessibility across developed and emerging economies.
However, factors such as high treatment costs for biologics, medication adherence challenges, and pricing pressures in regulated markets may limit market growth to some extent. Policies such as China's volume-based procurement and aggressive drug price negotiations continue to compress profit margins for pharmaceutical manufacturers despite improving patient access. Nevertheless, expanding healthcare infrastructure, rising awareness regarding fracture prevention, and increasing healthcare spending are expected to support long-term market expansion globally.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the Anti-Osteoporosis And Fracture Healing Market based on the following parameters - company highlights, service portfolio, key developments, financial performance, and strategies
- Key companies covered as a part of this study include Radius Health Inc., Pfizer Inc., Amgen Inc., Novartis AG, GlaxoSmithKline Plc., Merck & Co., Inc., F. Hoffman-La Roche AG, Eli, Lilly and Company Limited, and PhytoHealth Corporation
- Insights from this report would allow marketers and management authorities to make informed decisions regarding future service innovations, market expansion, and strategic partnerships
- The Anti-Osteoporosis And Fracture Healing Market report caters to various stakeholders including investors, service providers, pharmaceutical companies, regulatory bodies, and financial analysts
- Stakeholders would benefit from structured analytical frameworks and strategy matrices used in evaluating the Anti-Osteoporosis And Fracture Healing Market
Market Segmentation
- By Drug Class (Revenue, USD Bn, 2026-2033)
- Bisphosphonates
- Alendronate
- Risedronate
- Ibandronate
- Zoledronic acid
- Hormone replacement therapy
- Estrogen
- Progestin
- Others
- Monoclonal Antibodies
- Denosumab
- Romosozumab
- Anabolic Agents
- Alendronate
- Teriparatide
- Others
- By Route of Administration (Revenue, USD Bn, 2026-2033)
- Oral
- Injection
- By Distribution Channel (Revenue, USD Bn, 2026-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region (Revenue, USD Bn, 2026-2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Key Players
- Radius Health Inc.
- Pfizer Inc.
- Amgen Inc.
- Novartis AG
- GlaxoSmithKline Plc.
- Merck & Co., Inc.
- Hoffman-La Roche AG
- Eli, Lilly and Company Limited
- PhytoHealth Corporation
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Product Approval
- Collaboration/Merge/Acquisition
- Regulatory Landscape
- PEST Analysis
- Porter's Five Forces Analysis
- Epidemiology
- Robust Pipeline Analysis
4. Global Anti-Osteoporosis And Fracture Healing Market, By Drug Class, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Bisphosphonates
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Alendronate
- Risedronate
- Ibandronate
- Zoledronic acid
- Hormone replacement therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Estrogen
- Progestin
- Others
- Monoclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Denosumab
- Romosozumab
- Anabolic Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Alendronate
- Teriparatide
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
5. Global Anti-Osteoporosis And Fracture Healing Market, By Route of Administration, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
6. Global Anti-Osteoporosis And Fracture Healing Market, By Distribution Channel, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
7. Global Anti-Osteoporosis And Fracture Healing Market, By Region, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Company Profile
- Radius Health Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- GlaxoSmithKline Plc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- F. Hoffman-La Roche AG
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Eli
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Lilly and Company Limited
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- PhytoHealth Corporation
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Analyst Views
- Radius Health Inc.
9. Section
- References
- Research Methodology
- About Us
